Biocompatible antiseptic composition containing 9-hydroxycalabaxanthone and/or related xanthones The present invention relates to a cosmetic or pharmaceutical composition containing 9-hydroxycalabaxanthone in the form of gel, aqueous solution, soap, or other presentations, which can be used efficiently in the antiseptic treatment of the buccal cavity, as well as in the disinfection of surfaces such as body surfaces, for example, in the treatment of medical conditions associated with infection (such as acute or chronic wounds, burns, and surgical wounds), or disinfection of the skin before a surgical procedure.
A method and electronic system for inferring of a Morphological Neural Network (MNN), based on inference data including an input data vector. The MNN includes at least one morphological hidden layer and an output linear layer, a first matrix of neuron weights associated with the morphological hidden layer, and a second matrix of neuron weights associated with the output linear layer.
12163333 is =O. The invention also provides an in vitro method for eliminating and/or preventing the formation of monosodium urate monohydrate crystals in a composition, and an in vitro use of a compound of formula (I) for eliminating and/or preventing the formation of monosodium urate monohydrate crystals.
A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/4152 - 1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
The present invention relates to an aminosquaramide polymer comprising a backbone of repeating structural units, being these repeating structural units equal or different and selected from the group consisting of: monomer of formula (A) (or a salt thereof), and monomer of formula (B) (or a salt thereof); and a conjugate comprising the aminosquaramide polymer and one or more molecules of interest. It also refers to compositions containing the polymer or the conjugate; and processes for their preparation, as well as their uses as a carrier, in therapy, in diagnostic, in cosmetic and as a transfecting agent.
The present invention relates to an aminosquaramide polymer comprising a backbone of repeating structural units, being these repeating structural units equal or different and selected from the group consisting of: monomer of formula (A) (or a salt thereof), and monomer of formula (B) (or a salt thereof); and a conjugate comprising the aminosquaramide polymer and one or more molecules of interest. It also refers to compositions containing the polymer or the conjugate; and processes for their preparation, as well as their uses as a carrier, in therapy, in diagnostic, in cosmetic and as a transfecting agent.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
Method and Electronic system for non-iterative training of a neural network, based on training data including an input data matrix and an output data matrix, the output data matrix being expected for said input data matrix, the training resulting in a matrix of weights of the neural network.
G06F 7/544 - Methods or arrangements for performing computations using exclusively denominational number representation, e.g. using binary, ternary, decimal representation using non-contact-making devices, e.g. tube, solid state deviceMethods or arrangements for performing computations using exclusively denominational number representation, e.g. using binary, ternary, decimal representation using unspecified devices for evaluating functions by calculation
The present invention relates to a thermoelectric device for measuring stress in photosynthetic organisms (11), stress which is caused by high and/or low temperatures, ultraviolet (UV) radiation and/or high photosynthetically active radiation (PAR), said device being configured to be coupled to a fluorometer (21) and/or an ultraviolet (UV) radiation source and/or a high photosynthetically active radiation (PAR) source (23). The thermoelectric device comprises a thermoelectric unit (5), a heat plate (31), a heat sink (61), temperature control means (62) and an energy source (8), configured to house at least one removable plate (34), with a housing (34a) for a sample (1) of a photosynthetic organism (11), in order to develop a small device specifically designed to subject various samples (1) of photosynthetic organisms housed in a heating block at the desired conditions and be able to perform the chlorophyll fluorescence measurements.
Biocompatible antiseptic composition containing 9-hydroxycalabaxanthone and/or related xanthones The present invention relates to a cosmetic or pharmaceutical composition containing 9-hydroxycalabaxanthone in the form of gel, aqueous solution, soap, or other presentations, which can be used efficiently in the antiseptic treatment of the buccal cavity, as well as in the disinfection of surfaces such as body surfaces, for example, in the treatment of medical conditions associated with infection (such as acute or chronic wounds, burns, and surgical wounds), or disinfection of the skin before a surgical procedure.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
8.
METHOD AND ELECTRONIC SYSTEM FOR INFERRING A MORPHOLOGICAL NEURAL NETWORK
Method and electronic system for inferring of a Morphological Neural Network (MNN), based on inference data including an input data vector, wherein the MNN comprises at least one morphological hidden layer and an output linear layer, a first matrix of neuron weights associated with the morphological hidden layer, and a second matrix of neuron weights associated with the output linear layer.
Described are fatty acids with one or more unsaturations, having an odd hydrocarbon chain, the fatty acids having the chemical structure of the therapeutically active metabolites of even-chain mono- or polyunsaturated alpha-hydroxylated fatty acids. Also described are compositions comprising said fatty acids, medical uses thereof, and the use thereof as indicators of the efficacy of and/or response to the treatment of a patient with the even-chain mono- or polyunsaturated alpha-hydroxylated fatty acids from which they are derived.
A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
It is provided a composition comprising phytic acid or a pharmaceutically acceptable salt thereof, for use in reducing or preventing microorganisms' proliferation and/or encrustations caused by a urinary tract device implanted in a subject, thereby preventing or treating clinical complications related to microorganisms' proliferation and/or encrustations. The composition can further comprise a urine acidifier such as methionine, a crystallization inhibitor such as theobromine and/or other agents.
A61K 31/6615 - Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
A61L 29/16 - Biologically active materials, e.g. therapeutic substances
The present invention consists of a stochastic signal generation element comprising a binary to stochastic converter, which in turn comprises a first input for receiving a binary signal and a second input for receiving a random signal, and which is configured to convert said binary signal into a first stochastic signal using said random signal, the stochastic signal generation element being characterized in that it comprises a processing unit with a first input for receiving said first stochastic signal and a second input for receiving a reference stochastic signal, the latter being generated from a constant value signal and using said random signal, processing them according to at least one arithmetic function, the result whereof is a stochastic output signal representative of said processing. It further consists of a computational neuron that implements said stochastic signal generation element, likewise a neural network that implements said computational neuron.
The present invention relates to an aminosquaramide polymer comprising a backbone of repeating structural units, being these repeating structural units equal or different and selected from the group consisting of: monomer of formula (A) (or a salt thereof), and monomer of formula (B) (or a salt thereof); and a conjugate comprising the aminosquaramide polymer and one or more molecules of interest. It also refers to compositions containing the polymer or the conjugate; and processes for their preparation, as well as their uses as a carrier, in therapy, in diagnostic, in cosmetic and as a transfecting agent.
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 9/00 - Medicinal preparations characterised by special physical form
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
The invention relates to a process for storing protein-decorated nanoparticles on paper substrates without irreversible binding, and particularly for storing protein-decorated nanoparticles within paper substrates modified with a polymer. The invention also relates to a reservoir containing protein-decorated nanoparticle capable of stablishing biological interactions obtained by the process and its use in biosensors made of paper.
G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
G01N 33/52 - Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper
G01N 33/531 - Production of immunochemical test materials
G01N 33/544 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
Method and Electronic system for non-iterative training of a neural network, based on training data including an input data matrix and an output data matrix, the output data matrix being expected for said input data matrix, the training resulting in a matrix of weights of the neural network.
Compounds of formula I, their respective mirror-image enantiomers, and mixtures—preferably racemic—of both enantiomers, wherein R1 is ethyl or phenyl; R2 is methyl, phenyl, monosubstituted phenyl, benzyl, or monosubstituted benzyl; R3 is selected from the group consisting of: (C1-C6)-alkyl, (C1-C6)-cycloalkyl, —[CH2]n-phenyl, —[CH2]n-1-naphtyl, —[CH2]n-2-naphtyl, and —[CH2]n-[substituted phenyl]; wherein [substituted phenyl] is a phenyl radical with one, two or three substituents independently selected from: F, Cl, Br, (C1-C3)-alkyl, (C1-C3)-alkyloxy, phenyl, phenoxy, —CF3, —OCF3, nitro, —CN, —CO—(C1-C3)-alkyl and benzoyl; and n is an integer between 0 and 4; have a high affinity for imidazoline receptors of the I2 type, i.e. they are I2-IR ligands. Consequently they are applicable in the prevention or treatment of brain disorders in animals, including humans, particularly of neurodegenerative disorders, and more particularly of Alzheimer's disease (AD).
Compounds of formula I, their respective mirror-image enantiomers, and mixtures—preferably racemic—of both enantiomers, wherein R1 is ethyl or phenyl; R2 is methyl, phenyl, monosubstituted phenyl, benzyl, or monosubstituted benzyl; R3 is selected from the group consisting of: (C1-C6)-alkyl, (C1-C6)-cycloalkyl, —[CH2]n-phenyl, —[CH2]n-1-naphtyl, —[CH2]n-2-naphtyl, and —[CH2]n-[substituted phenyl]; wherein [substituted phenyl] is a phenyl radical with one, two or three substituents independently selected from: F, Cl, Br, (C1-C3)-alkyl, (C1-C3)-alkyloxy, phenyl, phenoxy, —CF3, —OCF3, nitro, —CN, —CO—(C1-C3)-alkyl and benzoyl; and n is an integer between 0 and 4; have a high affinity for imidazoline receptors of the I2 type, i.e. they are I2-IR ligands. Consequently they are applicable in the prevention or treatment of brain disorders in animals, including humans, particularly of neurodegenerative disorders, and more particularly of Alzheimer's disease (AD).
C07F 9/6561 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Measuring, detecting, monitoring and controlling devices; Testing and quality control devices; Scientific research and laboratory apparatus, educational apparatus and simulators; Databases; Test benches; Test benches; Laboratory instrument for the detection of pathogens and toxins in a biological sample for research use; Computer software applications, downloadable. Science and technology services; Biological research laboratory services; Biomedical research services; Laboratory services for analytical testing; Biological research and analysis; Preparation of biological samples for testing and analysis in research laboratories. Medical services; Human tissue bank services; Clinical services for kidney and urinary tract stones.
18.
ELEMENT FOR GENERATING STOCHASTIC SIGNALS, STOCHASTIC NEURON AND NEURAL NETWORK BASED ON SAID NEURON
The present invention relates to an element for generating stochastic signals, comprising a first binary-to-stochastic converter that includes a first input for receiving a binary signal and a second inlet for receiving a random signal and which is configured to convert the binary signal into a first stochastic signal using the random signal. The element for generating stochastic signals is characterised in that it comprises a processing unit with a first input for receiving the first stochastic signal and a second input for receiving a reference stochastic signal, the latter being generated from a constant-value signal and using the random signal. The signals are processed according to at least one arithmetic function, the result of which is a stochastic output signal representative of that processing. The invention also relates to a computational neuron that implements the element for generating stochastic signal, and to a neural network that implements the computational neuron.
Described are fatty acids with one or more unsaturations, having an odd hydrocarbon chain, the fatty acids having the chemical structure of the therapeutically active metabolites of even-chain mono- or polyunsaturated alpha-hydroxylated fatty acids. Also described are compositions comprising said fatty acids, medical uses thereof, and the use thereof as indicators of the efficacy of and/or response to the treatment of a patient with the even-chain mono- or polyunsaturated alpha-hydroxylated fatty acids from which they are derived.
C07C 59/42 - Unsaturated compounds containing hydroxy or O-metal groups
A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
It is provided a composition comprising phytic acid or a pharmaceutically acceptable salt thereof, for use in reducing or preventing microorganisms' proliferation and/or encrustations caused by a urinary tract device implanted in a subject, thereby preventing or treating clinical complications related to microorganisms' proliferation and/or encrustations. The composition can further comprise a urine acidifier such as methionine, a crystallization inhibitor such as theobromine and/or other agents.
The invention relates to a process for storing protein-decorated nanoparticles on paper substrates without irreversible binding, and particularly for storing protein-decorated nanoparticles within paper substrates modified with a polymer. The invention also relates to a reservoir containing protein-decorated nanoparticle capable of stablishing biological interactions obtained by the process and its use in biosensors made of paper.
G01N 33/52 - Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper
G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
G01N 33/544 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
The invention relates to a method, which is a decentralised application based on a blockchain for monitoring certified and confidential notifications and deliveries of messages or data files to at least one recipient, proof of non-repudiation of sending and receipt being generated, and for monitoring the notification result: participants, timestamp of the moment of notification and final status. The method controls the flow of the exchange of data and proofs by means of smart contract functions invoked by the sender and the recipient(s), without trusted third parties intervening to handle the process or resolve conflicts between parties. The content of the notification is not kept in the blockchain; however, from the data stored by the smart contract, it can be confirmed that the data provided by any of the participants correspond to the date of the exchange, including the message. Alternatively, it is possible to deliver public messages that can be accessed through the smart contract.
H04L 9/06 - Arrangements for secret or secure communicationsNetwork security protocols the encryption apparatus using shift registers or memories for blockwise coding, e.g. D.E.S. systems
G06F 16/00 - Information retrievalDatabase structures thereforFile system structures therefor
23.
Combined preparations of urinary acidifiers and crystallization inhibitors and application thereof for the treatment or prevention of phosphatic or calcium phosphate-induced renal lithiasis
The present invention is related to the use of a separate, sequential or simultaneous combination of at least one urinary acidifier with at least one calcium phosphate crystallization inhibitor for urine acidification, and thus preventing the pH at which supersaturation of calcium phosphate is produced and consequently, renal lithiasis.
12316162n2n2n2n13133313222-IR ligands. Consequently they are applicable in the prevention or treatment of brain disorders in animals, including humans, particularly of neurodegenerative disorders, and more particularly of Alzheimer's disease (AD).
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The invention relates to a mood recognition method for recognizing the mood of a subject (1) based on their relationship with facial expressions/movements. The method of the invention focuses on recognizing moods, a concept that is different from emotion. The manner of transforming the captured images of the subjects (1) into facial movements is customized, by learning the particular form of the facial features of the analyzed subject (1). The invention is based on the analysis of a set of a given number of images, but said number being greater than the number used in standard emotion recognition. A more robust mood recognition method is thereby defined. The method comprises three fundamental steps: defining general previous criteria and data, defining customized resting patterns, and evaluating the mood.
Alpha-derivatives of cis-monounsaturated fatty acids for use as medicines. The present invention refers to pharmaceutically acceptable compounds of Formula I, their salts and derivatives, where (a) and (b) can take any value between 0 and 14, (X) can be substituted by any atom or group of atoms with an atomic/molecular weight between 4 and 200 Da and (R) can be substituted by any atom or group of atoms with an atomic/molecular weight between 1 and 200 Da, for use as medicines.
A61K 31/185 - AcidsAnhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
A61K 31/231 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
Method for active reinforcement against shear stress or shear failure in structural load-bearing elements such as beams, pillars and slabs in which is provided at least one bar, wire, strip or similar reinforcement element (3) in a shape-memory alloy pre-stretched in the martensite phase around the structural load-bearing element (1), crosswise to a fissure (2) that is generated or which may be generated by the shear force or shear failure. The reinforcement element (3) is subsequently anchored around the structural load-bearing element (1), such anchoring being achieved by overlapping at least two sections of the linear reinforcement element itself. Subsequently the reinforcement element (3) is activated by heating, causing its transformation from the martensite phase to the austenite phase. In addition, the invention relates to a system for active reinforcement with at least one similar reinforcement element (3) in shape-memory alloy.
The present invention relates to hydroxy-triglycerides, their synthesis, a pharmaceutical and/or nutraceutical composition which comprises at least one of said hydroxy-triglycerides, and a method which comprises the administration to a patient of a therapeutically effective quantity of at least one of said hydroxy-triglycerides or at least one of said pharmaceutical and/or nutraceutical compositions, for the prevention and/or treatment of at least one disease selected from cancer, metabolic/cardiovascular diseases, and/or neurological/inflammatory diseases.
C07C 69/732 - Esters of carboxylic acids having esterified carboxyl groups bound to acyclic carbon atoms and having any of the groups OH, O-metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
C11C 3/00 - Fats, oils or fatty acids obtained by chemical modification of fats, oils or fatty acids, e.g. by ozonolysis
C11C 3/06 - Fats, oils or fatty acids obtained by chemical modification of fats, oils or fatty acids, e.g. by ozonolysis by esterification of fats or fatty oils with glycerol
C07C 51/367 - Preparation of carboxylic acids or their salts, halides, or anhydrides by reactions not involving formation of carboxyl groups by introduction of functional groups containing oxygen only in singly bound form
C07C 67/08 - Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
C07C 67/327 - Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by splitting-off hydrogen or functional groupsPreparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by hydrogenolysis of functional groups by elimination of functional groups containing oxygen only in singly bound form
29.
PHARMACEUTICAL COMPOSITION COMPRISING 5-DODECANOLIDE, PREPARATION THEREOF AND USE OF SAME
The invention relates to a pharmaceutical composition comprising 5-dodecanolide as an active ingredient. This active ingredient is isolated from pig lard using a specific treatment. The invention, therefore, also relates to a method for obtaining the composition of the invention, and to the use of same for therapeutic purposes and, more specifically, for the purpose of treating inflammation.
The invention relates to a method for communications in CAN ("Controller Area Network") networks and a signal concentrator (3) that performs said method. More concretely, said signal concentrator (3) for CAN networks comprises: an input/output module (8), a series of links (2) connected to said input/output module (8), a signal coupler (9), and a masking module (17), which allows an increase in the failure detection capacity and a decrease in the likelihood of the communications being blocked by defects in the devices forming part of said network.
The present invention refers to the use of theobromine or its derivatives as an inhibitor of the crystallization of uric acid to avoid the formation of uric acid crystals in urine and as a consequence renal lithiasis or specifically uric acid renal lithiasis.
The present invention is related to a composition comprising phytic acid or a phytate salt, magnesium in the form of salt, hydroxide or oxide and optionally at least one polyphenol. These components may be in isolated form or be part of an enriched plant extract. The invention is also related to the use of this composition for the treatment of renal lithiasis, preferably calcium or calcium oxalate lithiasis, either in the form of a medicament, a nutraceutical or functional food or food supplement.
SERVEI DE SALUT DE LES ILLES BALEARS - IBSALUT (Spain)
Inventor
Grases Freixedas, Félix
Costa Bauza, Antonia
Adrover Estelrich, Miquel
Berga Montaner, Francisco
Sanchís Cortés, Pilar
Masmiquel Comas, Luis
Rivera Irogoin, Rosmeri
Fortuny Marqués, Regina
Abstract
The invention relates to the use of phytate or any of the salts thereof for preventing the formation of advanced glycation end-products (AGE), toxic products that are produced in pathologies such as diabetes, either alone or combined with B6 vitamins such as pyridoxamine and forming part of a medicament or a pharmaceutical composition produced so as to be administered via oral, rectal, subcutaneous, intraarterial, intramuscular, intraspinal, intracraneal, intravenous or inhalation routes.
The invention relates to the use of cyclic oligosquaramides formed by two squaramide units as transfection agents for transporting genetic material into the cell.
The present invention relates to hydroxy-triglycerides, their synthesis, a pharmaceutical and/or nutraceutical composition which comprises at least one of said hydroxy- triglycerides, and a method which comprises the administration to a patient of a therapeutically effective quantity of at least one of said hydroxy-triglycerides or at least one of said pharmaceutical and/or nutraceutical compositions, for the prevention and/or treatment of at least one disease selected from cancer, metabolic/cardio vascular diseases, and/or neurological/inflammatory diseases.
C07C 69/732 - Esters of carboxylic acids having esterified carboxyl groups bound to acyclic carbon atoms and having any of the groups OH, O-metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
C11C 3/00 - Fats, oils or fatty acids obtained by chemical modification of fats, oils or fatty acids, e.g. by ozonolysis
A61K 31/231 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The invention relates to a composition containing phytic acid or a phytate salt, magnesium in the form of salt, hydroxide or oxide and optionally at least one polyphenol. These compounds can be in the isolated form or form part of an enriched plant extract. The invention also relates to the use of this composition for the treatment of renal lithiasis, preferably calcium or oxocalcium, in the form of a drug, nutraceutical or functional food, or food supplement.
The invention relates to the use of theobromine or its derivatives as a uric acid crystallisation inhibitor in order to prevent the formation of crystals of uric acid in urine and, consequently, renal lithiasis or in particular uric renal lithiasis.
Alpha-derivatives of cis-monounsaturated fatty acids for use as medicines. The present invention refers to pharmaceutically acceptable compounds of Formula I, their salts and derivatives, where (a) and (b) can take any value between 0 and 14, (X) can be substituted by any atom or group of atoms with an atomic/molecular weight between 4 and 200 Da and (R) can be substituted by any atom or group of atoms with an atomic/molecular weight between 1 and 200 Da, for use as medicines.
A61K 31/185 - AcidsAnhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
A61K 31/231 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
The invention relates to the use of a separate, sequential or simultaneous combination of at least one urinary basifying agent with at least one uric acid crystallisation inhibitor in order to basify urine and thus prevent pH at which renal lithiasis occurs.
A61K 31/191 - Acyclic acids having two or more hydroxy groups, e.g. gluconic acid
A61K 31/194 - Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
The invention relates to the use of a separate, sequential or simultaneous combination of at least one urinary acidifier with at least one calcium phosphate crystallisation inhibitor in order to acidify urine and thus prevent pH at which calcium phosphate supersaturation and, consequently, renal lithiasis occur.
CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED FISIOPATOLOGÍA DE LA OBESIDAD Y NUTRICIÓN (Spain)
Inventor
Palou Oliver, Andreu
Picó Segura, Catalina
Konieczna, Jadwiga
Sánchez Roig, Juana
Palou March, Mariona
Abstract
The invention relates to a method for predicting and/or preventing overweight, obesity and/or disorders associated with overweight or obesity, said method comprising the detection of the product of the expression of the LRP11 gene, and also of LRP11 in combination with certain genes. In addition, the method permits a personalised treatment to be designed for a subject with the risk of developing said diseases, and permits the effectiveness of a treatment, involving the ingestion of leptin, to be evaluated. The invention also relates to: the use of the products of expression of the genes according to the invention as biomarkers for said diseases; a kit that detects the products of expression; and the use of same for said indications.
The invention relates to the synthesis and use of compounds comprising squaramide for the treatment of diseases of parasitic origin, such as American trypanosomiasis also known as Chagas disease, or leishmaniasis.
This invention relates to a composition that comprises inositol phosphates and/or bisphosphonates, and to the use thereof to prevent the loss of substances of biological interest in the body of patients subjected to dialysis and to maintain sufficient physiological levels of said substances to regulate physiological and/or pathological processes, these substances being inhibitors of pathological crystallization.
This invention refers to the synthesis and purification of 2 hydroxide derivatives of fatty acids, as well as to the separation method of its enantiomers (or optic isomers) [−] y [+], to the enantiomers themselves, to pharmaceutical compositions which include them, and to their use as medicines, as well as to an in vitro method of diagnosis/prognosis and evaluation of the potential use of the molecules of the invention in different pathologies, as well as their use for the regulation of certain enzymes and the study of their activity and effects.
A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
C07C 59/42 - Unsaturated compounds containing hydroxy or O-metal groups
C07C 51/493 - SeparationPurificationStabilisationUse of additives by treatment giving rise to chemical modification whereby carboxylic acid esters are formed
45.
METHOD AND SYSTEM FOR FORECASTING AIRPORT CONGESTION IN AN AIR TRAFFIC NETWORK
The invention relates to a method for forecasting airport traffic in an air traffic network that combines an algorithm based on queues, and the relations between the actual flights of the planning of each airline, said method being characterised in that it establishes a simulation based on the rotation of each aircraft, the connecting flights, airport congestion and random delays, a fifth factor simulating external disturbances, and an airport management method being established independently of the simulation process.
The invention relates to a fixed-dose association of phytate and zinc in synergic proportions for use in the treatment of crystallization of hydroxyapatite. Advantageously, said association is in a molar ratio between the phytate and the zinc exceeding 4:1. The invention also relates to the use of said association for manufacturing a drug for the treatment, prophylaxis and/or prevention crystallization of hydroxyapatite in humans.
Probabilistic digital system for efficiently exploring large databases, which system comprises an input of n+1 vectors, 'n' of which belong to the database and one of which is the pattern to be identified, vector x0 (1); wherein each vector will consist of N numbers or descriptors, each defined by 'm' bits, and wherein each of these components of 'm' bits will represent a descriptor determined for the object which describes each vector; such that each object is determined by N different descriptors each coded with 'm' bits, and wherein the quantities described by each descriptor will have to be normalized to the range covered thereby; and wherein the database to be scanned will return a total of n vectors (2), each of which will be compared with the reference vector x0 (1) in a plurality of vector comparators (3).
The invention relates to a minitransposon comprising left and right inverted repeats of ISPst9, and to the use thereof for transferring a nucleic acid or for random mutagenesis. In addition, the invention relates to a method for the transposition of a nucleic acid from a donor bacterium to a recipient bacterium, comprising introducing the nucleic acid to be transposed between the inverted repeats of the minitransposon of the invention, introducing the minitransposon into the donor bacterium and conjugating the donor and recipient bacteria.
C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
C12N 15/78 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Pseudomonas
C12N 15/73 - Expression systems using phage lambda regulatory sequences
The invention describes a device capable of maintaining communication channels of various natures and a service for providing both stored and real-time information obtained via the connection to other devices or systems; such that the information is automatically provided to other apparatuses which are within the wireless coverage area thereof.
Method for carrying out transactions with digital banknotes. The method is applicable to digital banknotes provided with an identifier, a validity test and an item of information relating to a usage right associated with said digital banknote, comprising the following steps: a. a proprietary user UP sends a transaction offer for the digital banknote; b. a receiving user UR verifies the validity test of said digital banknote; c. a transfer request from said UR to said UP is generated; d. said UP verifies said transfer request and said UP generates a transfer acceptance; e. said UR verifies said transfer acceptance; and f. the digital banknote is transferred to the UR who acquires the usage right.
The present invention relates to a method for determining inositol phosphates in biological samples and comprises the following steps: placing the sample in contact with a solid ion exchanger using a static bath technique; isolating the solid ion exchanger from the rest of the unreacted sample; removing the inositol phosphate retained on the ion exchanger; and detecting the inositol phosphate extracted. The invention furthermore comprises the method for detecting the inositol phosphate and a kit for implementing any of said methods.
Closure element for prefabricated modular building, which comprises a panel (1) provided with edges (3, 4, 5, 6) and also comprises at least one structural element secured to at least one of the edges of the closure panel and provided with projecting and recessed portions for achieving male/female joins between said closure element and at least one of the structural support elements (17, 25, 33).
E04B 2/70 - Walls of framework or pillarworkWalls incorporating load-bearing elongated members with elongated members of wood
E04B 2/26 - Walls having cavities in, but not between, the elements, i.e. each cavity being enclosed by at least four sides forming part of one single element the walls being characterised by fillings in all cavities in order to form a wall construction
E04C 2/38 - Building elements of relatively thin form for the construction of parts of buildings, e.g. sheet materials, slabs, or panels characterised by the shape or structure with attached ribs, flanges, or the like, e.g. framed panels
53.
ENANTIOMERS OF 2-HYDROXY DERIVATIVES OF FATTY ACIDS
The invention relates to enantiomers of 2-hydroxy derivatives of fatty acids. The invention refers to the synthesis and purification of 2-hydroxy derivatives of fatty acids, and to the method for separating the enantiomers (or optical isomers) [-](S) and [+](R) of 2-hydroxy derivative compounds of fatty acids, to the actual enantiomers, to pharmaceutical compositions that include same and to the use thereof as drugs, as well as to in vitro diagnosis/prognosis methods and to methods for assessing the potential use of the molecules of the invention, in various diseases, as well as to the use thereof for regulating certain enzymes and to the study of the activity and effects thereof.
C07C 59/42 - Unsaturated compounds containing hydroxy or O-metal groups
C07C 51/493 - SeparationPurificationStabilisationUse of additives by treatment giving rise to chemical modification whereby carboxylic acid esters are formed
A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
09 - Scientific and electric apparatus and instruments
16 - Paper, cardboard and goods made from these materials
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
Goods & Services
Identity cards, magnetic, scientific, nautical, surveying, electric, photographic, cinematographic, optical, weighing, measuring, signalling (warning lights), checking (supervision), life-saving and teaching apparatus and instruments; Apparatus for recording, transmission and reproduction of sound or images; Magnetic data carriers, recording discs; Cash registers; Calculating machine, Data-processing equipment and computers; Fire-extinguishing apparatus. Pamphlets, Catalogues, Forms, Stickers, Labels (not of textile), Calendars, Agenda books, Cards, Books, Periodicals (magazines), Printed publication, Book binding articles, Photographs, Stationary, Instructional or teaching material, Writing material, Printed publication, Printed matter, Paper, Cardboard and goods made from these materials included in this class. Organisation and conducting of congresses, conferences, symposiums, courses, artistic and sporting competitions, prize-giving events, publication of books and texts; Organization of exhibitions for cultural or educational purposes, Training services, Educational and teaching services. Scientific and technological services and research and design relating thereto; Industrial analysis and research services; Design and development of computer hardware and software.
55.
METHOD FOR PREVENTING TOTAL OR PARTIAL CRYSTALLIZATION OF OLIVE OIL DURING STORAGE AT LOW TEMPERATURE
The invention relates to a method for preventing the total or partial crystallization of olive oil during storage at low temperature, while retaining the physical/chemical and sensory properties, which includes the application of ultrasonic energy to said olive oil. The invention also relates to the olive oil obtained from said method.
A23B 7/015 - Preserving by irradiation or electric treatment without heating effect
A23L 3/30 - Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by irradiation without heating by treatment with ultrasonic waves
The invention relates to compounds having formula (I), in which the meaning of the substituents is that indicated in the description. Said compounds can be used as fluorescent markers.
C07D 257/10 - Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
C07D 259/00 - Heterocyclic compounds containing rings having more than four nitrogen atoms as the only ring hetero atoms
G01N 33/52 - Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper
57.
cis-monounsaturated fatty acids intended for use as a drug
Alpha-derivatives of cis-monounsaturated fatty acids for use as medicines. The present invention refers to pharmaceutically acceptable compounds of Formula I, their salts and derivatives, where (a) and (b) can take any value between 0 and 14, (X) can be substituted by any atom or group of atoms with an atomic/molecular weight between 4 and 200 Da and (R) can be substituted by any atom or group of atoms with an atomic/molecular weight between 1 and 200 Da, for use as medicines.
A61K 31/185 - AcidsAnhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
This invention relates to a composition that comprises inositol phosphates and/or bisphosphonates, and to the use thereof to prevent the loss of substances of biological interest in the body of patients subjected to dialysis and to maintain sufficient physiological levels of said substances to regulate physiological and/or pathological processes, these substances being inhibitors of pathological crystallization.
Portable device (1) for analysing pH or other variables by electrochemical measurement comprising a sensor (2), a microprocessor (3) and display means (4) for the results of the analysis. The portable device makes it possible to carry out pre-diagnoses quickly and easily without the need for specialist staff.
Method for establishing correspondence between a first digital image (U1) and a second digital image (U2), which method comprises the steps of: a) selecting a block B1(x) from U1 in a pre-determined manner, said block being centred on a pixel x of U1; b) selecting a series of blocks B2(yi) from U2 in the same manner as B1(x); c) for each B2(yi), calculating a distance between B2(yi) and B1(x) as a sum, weighted by f(x,z), of a function of the differences between values associated with the colour of the pixels in the same relative position z; and d) selecting the pixel yi which minimizes the distance between blocks, establishing a correspondence between pixels x and yi and giving the disparity of x as the difference yi-x, wherein f depends on x and z and is a non-constant decreasing function with respect to the modulus of the directional gradient of U1(x+z) in a pre-determined direction.
Device for characterizing current transients produced by ionizing particles interacting with a block of transistors in a logic gate, which device comprises a memory block with capacitors and a synchronization block, the memory block being provided with means for replicating said current and sending the latter to a plurality of outputs each connected to a branch to a capacitor by means of an evaluation switch, the synchronization block being able to generate, at regular intervals, control signals for opening the switches such that, during a current transient, the charge variation of the different capacitors via the evaluation switches is initiated at regular intervals, the approximate temporal profile of the integral of the current transient being able to be characterized from the states of charge of the capacitors.
G01R 31/00 - Arrangements for testing electric propertiesArrangements for locating electric faultsArrangements for electrical testing characterised by what is being tested not provided for elsewhere
62.
ALPHA-DERIVATIVES OF CIS-MONOUNSATURATED FATTY ACIDS INTENDED FOR USE AS A DRUG
The invention relates to alpha-derivatives of cis-monounsaturated fatty acids intended for use as a drug. More specifically, the invention relates to compounds having formula I, and the pharmaceutically acceptable derivatives and salts thereof, in which (a) and (b) can have any value between 0 and 14, (X) can be substituted by any atom or group of atoms with a weight between 4 and 200 Da, and (R) can be substituted by any atom or group of atoms with a weight between 1 and 200 Da, intended for use as a drug.
A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
A61K 31/185 - AcidsAnhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Use of squaramide-based macrocylic compounds as kinase inhibitors and as anti-tumour agents. More specifically, said compounds are used to treat diseases such as cancer, diabetes, neurodegenerative diseases, HIV replication, etc. Furthermore, the present invention likewise relates to pharmaceutical compositions that contain said compounds.
The present invention relates to a composition comprising phosphate and/or bisphosphonate inositols and their utilisation to prevent loss of substances of biological importance in the organism of patients subjected to dialysis and to maintain physiological levels of said substances sufficient to regulate physiological and/or pathological processes, the substances being inhibitory substances of pathological crystallisation.
The present invention relates to the use of myo-inositol hexaphosphate or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the prevention or treatment of a disease associated with the dissolution of crystals of calcium salts, in particular osteoporosis. These compounds may be utilized in the manufacture of functional foods, dietetic supplements, vitamin supplements, nutritional supplements, food supplements, or phytotherapeutic products having properties of inhibition of dissolution of crystals of calcium salts.
CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (Spain)
UNIVERSITAT DE LES ILLES BALEARS (Spain)
Inventor
Roig Broman, Daniel
Abstract
Submarine vehicle operated by remote control comprising the vehicle itself (1) and an external control unit for providing the vehicle (1) signals for controlling the propellers (14) for manoeuvring the vehicle (1) and managing the data signals from the vehicle (1) sensors and instruments. The vehicle (1) is configured modularly, integrating a plurality of modules for the functioning of the vehicle (1), and includes a non-hermetic self-supporting hull formed by at least two separable joined parts (110,111), with careening functions for reducing hydrodynamic resistance and chassis functions for the vehicle (1) modules, sensors and instruments, which are mounted on the hull (11) by means of securing elements fitted to the hull or by means of placing thereof in housings provided in the hull.
The invention relates to a fixed-dose association of 5 phytate and zinc in synergic proportions for use in the treatment of crystallization of hydroxyapatite. Advantageously, said association is in a molar ratio between the phytate and the zinc exceeding 4:1. The invention also relates to the use of said 10 association for manufacturing a drug for the treatment, prophylaxis and/or prevention crystallization of hydroxyapatite in humans.
The present invention is addressed to the use of leptin, a fragment of leptin or a mimetic product of leptin action, in the preparation of a pharmaceutical composition, a food composition and/or a nutritional supplement for the prevention of unhealthy food habits and/or cardiovascular disorders during adulthood.
The present invention relates to the utilisation of myo-inositol hexaphosphate or pharmaceutically-acceptable salts thereof for the manufacture of a medicament destined for the prevention or treatment of a disease associated with the dissolution of crystals of calcium salts, in particular osteoporosis. Said compound may be utilised in the manufacture of functional foods, dietetic complements, vitamin complements or nutritional complements or food complements or phytotherapeutic products having properties of inhibition of dissolution of crystals of calcium salts.
1 FIXED-DOSE ASSOCIATION OF PHYTATE AND ZINC The invention relates to a fixed-dose association of 5 phytate and zinc in synergic proportions for use in the treatment of crystallisation of hydroxyapatite. Advantageously, said association is in a molar ratio between the phytate and the zinc exceeding 4:1. The invention also relates to the use of said 10 association for manufacturing a drug for the treatment, prophylaxis and/or prevention crystallisation of hydroxyapatite in humans.
The present invention refers to the use of myo-inositol hexaphosphate or pharmaceutically acceptable salts thereof for the manufacture of a medicament for the prevention or treatment of an disease associated with the dissolution of crystals of calcium salts, in particular osteoporosis. Said compound may be utilised in the manufacture of functional foods, dietetic complements, vitamin complements, nutritional complements or food complements or phytotherapeutic products having properties of inhibition of dissolution of crystals of calcium salts.
This invention relates to a composition that comprises inositol phosphates and/or bisphosphonates, and to the use thereof to prevent the loss of substances of biological interest in the body of patients subjected to dialysis and to maintain sufficient physiological levels of said substances to regulate
physiological and/or pathological processes, these substances being inhibitors
Described are fatty acids with one or more unsaturations, having an odd hydrocarbon chain, the fatty acids having the chemical structure of the therapeutically active metabolites of even-chain mono- or polyunsaturated alpha-hydroxylated fatty acids. Also described are compositions comprising said fatty acids, medical uses thereof, and the use thereof as indicators of the efficacy of and/or response to the treatment of a patient with the even-chain mono- or polyunsaturated alpha-hydroxylated fatty acids from which they are derived.
A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
The present invention relates to hydroxy-triglycerides, their synthesis, a pharmaceutical and/or nutraceutical composition which comprises at least one of said hydroxy- triglycerides, and a method which comprises the administration to a patient of a therapeutically effective quantity of at least one of said hydroxy-triglycerides or at least one of said pharmaceutical and/or nutraceutical compositions, for the prevention and/or treatment of at least one disease selected from cancer, metabolic/cardio vascular diseases, and/or neurological/inflammatory diseases.
A61K 31/231 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
C07C 69/732 - Esters of carboxylic acids having esterified carboxyl groups bound to acyclic carbon atoms and having any of the groups OH, O-metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
C11C 3/00 - Fats, oils or fatty acids obtained by chemical modification of fats, oils or fatty acids, e.g. by ozonolysis
75.
COMPOSITION THAT COMPRISES CRYSTALLISATION INHIBITORY SUBSTANCES
This invention relates to a composition that comprises inositol phosphates and/or bisphosphonates, and to the use thereof to prevent the loss of substances of biological interest in the body of patients subjected to dialysis and to maintain sufficient physiological levels of said substances to regulate physiological and/or pathological processes, these substances being inhibitors of pathological crystallisation.
Described are fatty acids with one or more unsaturations, having an odd hydrocarbon chain, the fatty acids having the chemical structure of the therapeutically active metabolites of even-chain mono- or polyunsaturated alpha-hydroxylated fatty acids. Also described are compositions comprising said fatty acids, medical uses thereof, and the use thereof as indicators of the efficacy of and/or response to the treatment of a patient with the even-chain mono- or polyunsaturated alpha-hydroxylated fatty acids from which they are derived.
A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
